Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | ECE1 | P42892 | 12/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GHSR | Q92847 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051844 | 1.00 | ACE (0.65) | ACEECE1KDM4EAPAF1POLB | |
| SCHEMBL29749345 | 0.98 | ACE (0.63) | ACEECE1KDM4EAPAF1POLB | |
| SCHEMBL30051087 | 0.93 | ACE (0.75) | ACEECE1ERAP2 | |
| SCHEMBL30051359 | 0.92 | ACE (0.64) | ACEECE1KDM4EAPAF1POLB | |
| SCHEMBL30053239 | 0.91 | CTSC (0.66) | ACEECE1KDM4EAPAF1POLB | |
| SCHEMBL3497589 | 0.91 | ACE (0.72) | ACEECE1 | |
| SCHEMBL30051627 | 0.91 | ACE (0.72) | ACEECE1 | |
| SCHEMBL1228369 | 0.91 | ACE (0.78) | ACEECE1 | |
| SCHEMBL2488765 | 0.91 | ACE (0.78) | ACEECE1 | |
| SCHEMBL9235801 | 0.91 | ACE (0.78) | ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107647-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-06 | — | — | US | disclosed |
| US-11162952-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210072251-A9 | SINGLE MOLECULE PEPTIDE SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-03-11 | — | — | US | disclosed |
| US-20200124613-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | UNIV TEXAS (US) | 2020-04-23 | — | — | US | disclosed |
| US-10545153-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-28 | — | — | US | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107647-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, ANPEP, VIP | ACE 1689/4885ECE1 1401/4885KDM4E 455/4885 |
| US-11162952-B2 | Single molecule peptide sequencing | MICA, ANPEP, VIP | ACE 2420/4885ECE1 2628/4885KDM4E 4067/4885 |
| US-20210072251-A9 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, VIP, ANPEP | ACE 1809/4885ECE1 1123/4885KDM4E 751/4885 |
| US-20200124613-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, VIP, ANPEP | ACE 1809/4885ECE1 1123/4885KDM4E 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.